Clinical trial

HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy

NCT07848633

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE2

Study timeline

Study start (estimated)2026-10-01Date precision: day

Registry last updated2026-09-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER 2 Positive Advanced Breast Cancerunresolved

Interventions

- Oral paclitaxel solution: 200 mg/m² orally twice daily on Day 1 and Day 8 of each cycle, subcutaneous pertuzumab and trastuzumab fixed-dose combination for a total of 6 cyclesDRUG

Sponsors & collaborators

The First Affiliated Hospital with Nanjing Medical Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07848633 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.